Aquatic nervous necrosis virus detection method based on RT-LAMP-Cas14a without PAM limitation

Through the binding of RT-LAMP and Cas14a, the PAM sequence is used to design in RT-LAMP primers, breaking through the limitations of virus detection without PAM site, achieving high sensitivity and high specificity of neuronecrosis virus detection, and solving existing methods The problems of time-consuming, high cost and low sensitivity reduce economic losses and effectively cut off the spread of the virus.

CN119082370APending Publication Date: 2024-12-06HAINAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411380517.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing neuronecrosis virus detection methods are time-consuming, cost-effective, rely on professional and technical personnel and have low sensitivity. Especially, there are limitations in the detection of viruses without PAM sites, making it difficult to effectively detect neuronecrosis viruses.

Method used

Using the detection method of binding of RT-LAMP to Cas14a, the target fragment containing PAM sites was generated by adding PAM sequences to the RT-LAMP primers, and used in combination with CRISPR-Cas14a to achieve high sensitivity and high specificity detection without PAM dependence. .

Benefits of technology

It has achieved rapid, economical, high sensitivity and high specificity for neuronecrosis virus detection, breaking through the detection limit of PAM-free viruses, reducing economic losses, and effectively cutting off virus transmission.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082370A_ABST
    Figure CN119082370A_ABST
Patent Text Reader

Abstract

The invention provides a method for detecting nervous necrosis virus of grouper based on RT-LAMP-Cas14a without PAM (Polyacrylamide) limitation, which is based on a group of specific nervous necrosis virus RNA (Ribonucleic Acid) RT-LAMP amplification primers. According to the method, a PAM sequence is introduced to the 3'end of an FIP primer, a product is specifically recognized by CRISPR-Cas14a after constant-temperature amplification at 60 DEG C, then Cas14a enzyme is activated, and the non-specific trans-cleavage capability of the Cas14a enzyme is triggered. The invention specifically relates to the field of aquatic virus rapid diagnosis. Due to the fact that the RNA nucleic acid sequence of the nervous necrosis virus does not contain a PAM sequence recognized by Cas14a, RT-LAMP amplification primers are modified, RNA nucleic acid one-step amplification and CRISPR-Cas14a are combined, the limitation of a Cas14a detection technology is broken through, and a high-specificity and high-sensitivity detection technology is provided for the nervous necrosis virus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of important aquatic virus detection, and specifically relates to a method for detecting aquatic neuronecrosis virus based on RT-LAMP-Cas14a without PAM restriction. Technical Background

[0002] Neuronecrosis virus (NNV) belongs to the genus Betanodavirus of the family Nodaviridae and is mainly found in the cytoplasm of brain cells and retinal cells of infected fish. It is a non-enveloped dodecahedron with a diameter of about 25-34nm and contains two single-stranded RNA molecules, namely RNA 1 (3.1kb) and RNA2 (1.4kb). NNV can infect more than 40 species of fish, including Perciformes, Pleuronectiformes and Gadidae. NNV has a very high mortality rate for infected fish, which is mainly manifested by anorexia, decreased vitality, lying on one's side underwater without swimming, redness, swelling and ulceration of the lower jaw and caudal fin, and wide-open mouth after the onset of the disease. At present, there are two main methods for the defense and control of NNV: 1) disinfection and inactivation by physical or chemical methods; 2) prevention and control using vaccines (such as inactivated vaccines, protein vaccines and DNA vaccines). Unfortunately, there is currently no effective treatment for NNV in fish. Therefore, a sensitive and specific diagnostic method must be developed to control the spread of NNV in a timely and effective manner.

[0003] A variety of NNV detection methods have been reported, including traditional cell culture and electron microscopy, antibody-based fluorescent immunoassays, and nucleic acid-based polymerase chain reaction (PCR) and quantitative polymerase chain reaction (qPCR). However, these methods also have one or more significant drawbacks, such as time-consuming, high cost, reliance on professional technicians, and low sensitivity. The CRISPR-Cas (clustered regularly interspaced short palindromic repeats and associated proteins)-based diagnostic system provides a new platform for pathogen detection. The CRISPR-Cas system consists of a Cas endonuclease and a single-stranded guide RNA (sgRNA). Under the guidance of sgRNA, the Cas endonuclease recognizes the target and activates its trans-cleavage ability to non-specifically cleave single-stranded DNA (ssDNA) [25-27]. The combination of nucleic acid pre-amplification and the CRISPR-Cas system can significantly improve the sensitivity and specificity of detection. Cas14a's binding and cleavage (cis or trans cleavage) of ssDNA and its cis cleavage activity on PAM-dependent (TTTG / A) double-stranded DNA (dsDNA) both depend on the in situ adjacent motif (PAM). However, the related sequences of many viruses, such as neuronecrosis virus, do not contain PAM sequences, which limits the detection of related viruses. Summary of the invention

[0004] The present invention develops a highly sensitive and specific virus detection technology by combining RT-LAMP with Cas14a, which breaks through the detection method limitation of viruses without PAM sites, can effectively cut off virus transmission, reduce economic losses, and has broad application prospects.

[0005] In view of the above problems, the present invention aims to provide a method for detecting aquatic NNV based on RT-LAMP-Cas14a without PAM restriction. This method adds a PAM sequence to the RT-LAMP primer set, amplifies at 60°C, makes the target fragment contain a PAM site, and develops a new PAM-free NNV detection technology jointly with CRISPR-Cas14a.

[0006] In order to achieve the above object, the present invention adopts the following technical scheme:

[0007] The grouper neural necrosis virus RNA was extracted according to the magnetic bead method operation steps to obtain the RNA to be detected.

[0008] Design and synthesize the RT-LAMP primer set, the sequence is as follows: FIP-PAM: 5'-GACGCTGCTCCTTTCCCAC-TTTA-GAACAGTCCGACCCCAGT-3' BIP: 5'-GGAGTGTTCGATTGAGCGTTTGCCGACACACAGGAGT-3' F3: 5'-AGTCGTTGCCAAATGGTGG-3' B3: 5'-GCGGTAGTCTCTTCAGGTGT-3' LF: 5′-CAGAGGAGCGTGCGGGTG-3′ LB: 5'-GATGTGGTCAACGTGTCAG-3'

[0009] The RT-LAMP reaction system is as follows:

[0010]

[0011] The RT-LAMP amplification conditions are: 60° C., 45 min.

[0012] Agarose gel electrophoresis of RT-LAMP amplification products: Take 5 μL of the product and analyze it by 2% agarose gel electrophoresis. The ones with ladder-like bands are judged as positive, and those without bands are negative.

[0013] Prepare sgRNA using T7 RNA polymerase in vitro transcription kit.

[0014] The RT-LAMP amplification product was used as the sample to be detected and the CRISPR-Cas14a reaction system was used for detection.

[0015] The CRISPR-Cas14a reaction steps are as follows: 2 μM Cas14a, 1 μM sgRNA and 2 mM buffer (20 mM Tris-HCl, 20 mM NaCl, pH 9.0), incubated at 37 ° C for 20 minutes, then added 30 mM MgCl2, 500 mM ssDNA probe, 5 μL RT-LAMP amplification product, reacted at 37 ° C for 2 hours, and monitored the fluorescence signal (λ ex :492nm;λ em :520nm).

[0016] Molecular biology grade nuclease-free water was used as a blank control for the samples to be tested.

[0017] Fish not infected with NNV were used as negative controls for the tested samples.

[0018] The specific detection samples are: Escherichia coli, Vibrio parahaemolyticus, Pseudomonas aeruginosa, Klebsiella pneumoniae and Salmonella typhi.

[0019] The sensitivity detection method: 10 8 -10 1 aM neuronecrosis virus RNA was diluted in a 10-fold gradient and then detected by RT-LAMP-Cas14a.

[0020] The present invention utilizes one-step RT-LAMP to amplify the RNA of the neural necrosis virus, and does not need to be transcribed into cDNA before amplification, which greatly reduces the difficulty of operation. Because the related sequence of the neural necrosis virus does not have a PAM sequence, the possibility of constructing a Cas14 detection technology to detect it is limited. The present invention designs the RT-LAMP primer to break through the limitation of the PAM sequence, and makes full use of the characteristics of the Cas14a enzyme, thereby improving the sensitivity and specificity of the neural necrosis virus detection. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 RT-LAMP gel electrophoresis diagram, where lane 1 is the marker, lanes 2 and 3 are positive samples containing neuronecrosis virus nucleic acid, and lane 4 is the negative control.

[0022] Figure 2 Feasibility of RT-LAMP-Cas14a without PAM for detecting NAV.

[0023] Figure 3In Example 2, RT-LAMP-Cas14a without PAM detected neuronecrosis virus, Escherichia coli, Vibrio parahaemolyticus, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Salmonella typhi and negative samples.

[0024] Figure 4 Sensitivity test of RT-LAMP-Cas14a without PAM for detecting neural necrosis virus in Example 2. DETAILED DESCRIPTION

[0025] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments.

[0026] Example 1

[0027] The grouper neural necrosis virus RNA was extracted according to the magnetic bead method operation steps to obtain the RNA to be detected.

[0028] The RT-LAMP primer sequences were designed and synthesized as follows FIP-PAM: 5'-GACGCTGCTCCTTTCCCAC-TTTA-GAACAGTCCGACCCCAGT-3' BIP: 5'-GGAGTGTTCGATTGAGCGTTTGCCGACACACAGGAGT-3' F3: 5'-AGTCGTTGCCAAATGGTGG-3' B3: 5'-GCGGTAGTCTCTTCAGGTGT-3' LF: 5′-CAGAGGAGCGTGCGGGTG-3′ LB: 5'-GATGTGGTCAACGTGTCAG-3'

[0029] According to the following reaction system, each component was thawed on ice, added to a centrifuge tube and mixed, and then placed in a metal bath at 60°C for 40 minutes.

[0030]

[0031] Results analysis see Figure 1 , the positive samples amplified obvious ladder-like bands, while the negative samples did not.

[0032] Example 2 Feasibility verification of RT-LAMP-Cas14a without PAM restriction: 2μM Cas14a, 1μM sgRNA and 2mM buffer (20mM Tris-HCl, 20mM NaCl, pH 9.0) were incubated at 37°C for 20 minutes, and then 30mM MgCl2, 500mM ssDNA probe, 5μL RT-LAMP amplification product were added, reacted at 37°C for 2h, and the fluorescence signal (λ ex :492nm;λ em :520nm).

[0031] Positive samples without PAM sequences in the RT-LAMP primer set and negative samples not infected with NNV were used as controls.

[0031] Results analysis see Figure 2 There was no significant difference in fluorescence signals between positive and negative LAMP products without PAM sequence, while there was a significant difference in fluorescence signals between positive and negative samples of LAMP products with additionally introduced PAM sequence.

[0032] Specificity verification: RNA samples of neuronecrosis virus, Escherichia coli, Vibrio parahaemolyticus, Pseudomonas aeruginosa, Klebsiella pneumoniae and Salmonella typhi were subjected to RT-LAMP-Cas14a reaction.

[0033] The results are analyzed as Figure 3 , only when the detection system contains NRV RNA can an obvious fluorescent signal be detected.

[0034] Sensitivity verification: Nervous necrosis virus RNA was diluted once in a 10-fold gradient to prepare 10 8 -10 1 The samples of aM were detected respectively according to the RT-LAMP-Cas14a established by the present invention to verify the sensitivity of the detection method.

[0035] The results are analyzed as Figure 4 , the present invention can detect 10 2 The viral RNA concentration was 1 aM.

Claims

1. A method for detecting aquatic neuronecrosis virus without PAM restriction based on RT-LAMP-Cas14a. It is characterized in that The designed RT-LAMP primer set can introduce the PAM sequence after isothermal amplification. The amplification product containing the PAM site can be specifically recognized by the Cas14a and sgRNA complex, and activate the trans-cleavage activity of Cas14, non-specifically cleave the ssDNA reporter probe to obtain a visual detection signal.

2. A method for detecting aquatic neuronecrosis virus based on RT-LAMP-Cas14a without PAM restriction as described in claim 1, Features: It includes a pair of inner primers FIP-PAM and BIP, a pair of outer primers F3 and B3, and a pair of loop primers LF and LB. The inner primer sequences are: FIP-PAM: 5'-GACGCTGCTCCTTTCCCAC-TTTA-GAACAGTCCGACCCCAGT-3' BIP: 5'-GGAGTGTTCGATTGAGCGTTTGCCGACACACAGGAGT-3' The outer primer sequence is: F3: 5'-AGTCGTTGCCAAATGGTGG-3' B3: 5'-GCGGTAGTCTCTTCAGGTGT-3' The loop primer sequence is: LF: 5′-CAGAGGAGCGTGCGGGTG-3′ LB: 5'-GATGTGGTCAACGTGTCAG-3'.

3. A method for detecting aquatic neuronecrosis virus based on RT-LAMP-Cas14a without PAM restriction as described in claim 1, It is characterized in that The sgRNA sequence is: GAACAGUCCGACCCCAGUAC.

4. A method for detecting aquatic neuronecrosis virus based on RT-LAMP-Cas14a without PAM restriction as described in claim 1, It is characterized in that The ssDNA sequence is: 5'6-FAM-TTTTTTTTTTTT-3'BHQ1.

5. A method for detecting aquatic neuronecrosis virus based on RT-LAMP-Cas14a without PAM restriction as described in claim 1, It is characterized in that The following steps are involved: (1) Extracting grouper neural necrosis virus RNA according to the magnetic bead method operation steps to obtain the RNA to be detected; (2) Perform RT-LAMP reaction on the RNA to be detected. The reaction reagents and conditions are as follows: 1×IsothermalAmplification Buffer, 6 mM MgSO 4 , dNTPs Mix 1.5 mM each, 1.6 µM FIP-PAM and BIP, 0.2 µM F3 and B3, 0.4 µM LF and LB, 1.2 mM betaine, 1.0 μL Bst DNA polymerase, 1.0 μL RTX reverse transcriptase, 1.0 μL neural necrosis virus RNA, DEPC water to 25 μL. Heat at 60℃ for 40 min; (3) sgRNA preparation, characterized in that sgRNA is prepared using a T7 RNA polymerase in vitro transcription kit; (4) Detection of RT-LAMP products using Cas14a. The detection steps are as follows: 2 µM Cas14a, 1 µM sgRNA and 2 mM buffer (20 mM Tris-HCl, 20 mM NaCl, pH 9.0), incubate at 37°C for 20 min, then add 30 mM MgCl 2 , 500 mM ssDNA probe, 5 μL RT-LAMP amplification product, react at 37 °C for 2 h, and monitor the fluorescence signal (λ ex : 492 nm; λ em : 520 nm); (5) The fluorescence signal value collected by the microplate reader is used to determine whether the sample to be tested is NAV. The negative control is a sample that is not infected with NAV. If the fluorescence signal is significantly higher than the negative control, it is judged as positive. If there is no significant difference, it is judged as negative.